Purpose: This study evaluates real-world outcomes, toxicities, and prescribing patterns of PARP inhibitors (PARPis) for the treatment of metastatic breast cancer (MBC).
Patients And Methods: Electronic health records of 62 MBC patients treated with olaparib (n = 48) or talazoparib (n = 14) at Mayo Clinic System between 2017 and 2022 were analyzed. Time-to-treatment-failure (TTF) was assessed utilizing the Kaplan-Meier method.
Purpose: We previously reported that postmenopausal women with estrogen receptor-α-positive breast cancer receiving adjuvant anastrozole 1 mg/day (ANA1) with estrone (E1) ≥1.3 pg/mL and estradiol (E2) ≥0.5 pg/mL [inadequate estrogen suppression (IES)] had a threefold increased risk of a breast cancer event.
View Article and Find Full Text PDFIntroduction: To date, there is no adherence estimator to identify risk of nonadherence prior to initiating oral oncolytics.
Methods: A workgroup was assembled through the National Community Oncology Dispensing Association and tasked with creating a tool to meet this need. Tool constructs were defined after a review of the literature identifying top barriers to adherence.
This study was conducted to describe the building layout and dimensions, characterize the bedding material, and observe the management practices in 42 compost-bedded pack (CBP) barns in Kentucky (USA). The average herd size found in the study was 90 cows and the breeds consisted of Jersey (6.8%), Holstein (72.
View Article and Find Full Text PDF